TCON TRACON Pharmaceuticals, Inc. gains 41% Sep 22, 2017

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company's other product candidates comprise TRC205, an endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. has collaboration agreements with National Cancer Institute and Santen. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. http://www.priceseries.com/trade/TCON-TRACON-Pharmaceuticals-Inc-stock-gains-41-percent-a-Trade-Record-by-priceSeries-2017083020170922.html